|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Neutral||Sell||Strong Sell||Strong Sell||Neutral|
|Technical Indicators||BUY||Strong Sell||Sell||Strong Sell||Strong Sell|
|Summary||Neutral||Strong Sell||Strong Sell||Strong Sell||Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Morning Doji Star||1W||1||Nov 12, 2017|
|Bullish doji Star||30||1||Nov 22, 2017 03:00PM|
|Three Outside Down||15||1||Nov 22, 2017 03:30PM|
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.Read More
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|National Futures Association (United States), National Securities Depository (India), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States)||$10000||Start Trading|
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.